The syndicate was joined by several new international investors including Debiopharm and Korys, the Colruyt's family office, and existing investors, including venture capital firm Gilde Healthcare Partners, family office Van Herk Group, Dutch bank ING Corporate Investments and Breedinvest, the holding company of the Blokker households goods stores.
Agendia, a US and Netherlands-based personalized medicine company for treating breast cancer, has raised $65m in its series F round from a consortium led by the Debiopharm Group, a Switzerland-based drugs company.
The syndicate was joined by several new international investors including Korys, the Colruyt’s family office, and existing investors, including venture capital firm Gilde Healthcare Partners, family office Van Herk Group, Dutch bank ING Corporate Investments and Breedinvest, the holding company of the Blokker households goods stores.
David…
